Mode
Text Size
Log in / Sign up
Phase 4 Completed N=38 Randomized Double-blind Treatment

Treatments for Psychogenic Nonepileptic Seizures (NES)

Convulsion, Non-Epileptic · Conversion Disorder · Depression · Stress Disorders, Post-Traumatic
Source: ClinicalTrials.gov NCT00159965 ↗
Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Jan 2011
Primary outcomePrimary: Number of Nonepileptic Seizures (NES) — 5.0; 6.0; 3.0; 6.0 seizures — p=0.29

Summary

The investigators propose that treatment of the comorbid disorders (depression, anxiety, and impulsivity) with sertraline in patients with lone psychogenic nonepileptic seizures (NES), will result in a decreased number of NES. The purpose of this study is to provide pilot testing and data to inform the future randomized controlled trial based on the hypothesis.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Nonepileptic Seizures (NES)
5.0; 6.0; 3.0; 6.0; 2.0; 5.0 0.29
SECONDARY
Beck Depression Inventory-II (BDI-II)
16.7; 22.1; 11.7; 17.0 >0.05
SECONDARY
Modified Hamilton Depression Scale (MHRS)
17.8; 16.8; 11.6; 13.3 >0.05
SECONDARY
Global Assessment of Functioning (GAF)
53.3; 49.1; 56.8; 52.0 >0.05
SECONDARY
Davidson Trauma Scale (DTS)
52.5; 48.1; 40.3; 43.4 >0.05
SECONDARY
Barratt Impulsivity Scale (BIS)
57.8; 72.6; 64.9; 66.2 >0.05
SECONDARY
Dissociative Experiences Scale (DES)
21.0; 17.4; 8.5; 12.1 >0.05
SECONDARY
Symptom Checklist 90 (SCL-90)
84.9; 109.4; 78.9; 91.4 >0.05
SECONDARY
Oxford Handicap Scale (OHS)
3.1; 3.4; 2.3; 2.6 >0.05
SECONDARY
Clinical Global Impressions - Severity (CGI-S)
4.9; 5.1; 3.3; 3.9 >0.05
SECONDARY
Clinical Global Impressions - Improvement (CGI-I)
2.9; 3.5 >0.05
SECONDARY
Family Assessment Device (FAD)
2.0; 2.0; 2.0; 2.2 >0.05
SECONDARY
Longitudinal Interval Follow-Up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)
11.8; 13.9; 11.8; 13.8 >0.05
SECONDARY
Quality of Life in Epilepsy-31 (QOLIE-31)
48.4; 38.2; 56.7; 46.9 >0.05

Eligibility Criteria

Inclusion Criteria

  • Video electroencephalogram (vEEG) confirmed diagnosis of NES
  • Have at least one nonepileptic seizure per month
  • Comorbid diagnosis of either depression, anxiety, or post traumatic stress disorder (PTSD)
  • Able to complete self report symptom scales
  • Not receiving optimized antidepressant medication

Exclusion Criteria

  • Equivocal electroencephalogram (EEG) findings
  • Current suicidality, litigation, or self-mutilation
  • Using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan
  • Allergy/sensitivity to sertraline
  • Current alcohol/drug dependence
  • Serious medical illness requiring current hospitalization
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00159965). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search